LDL-C is considered to be the major lipid risk factor and the main target of lipid-lowering therapy. Nevertheless, as all potentially atherogenic lipoprotein particles contain only one molecule of ...

NewAmsterdam Pharma's obicetrapib lowers LDL-C in Phase 3 trials, showing promise as a CETP inhibitor. Read more on NAMS ...

The company’s weight loss therapy was able to sustain itself for up to 40 days in obese patients after a single injection.

A 10-year study published in JAMA Network Open reveals that individuals in Japan who quit alcohol experienced higher levels ...

Epigenetic editing is a promising method for gene regulation in vitro and in vivo, allowing precise control of gene ...

In lipid-lowering trials, bile acid sequestrants, such as colesevelam, cholestyramine, colestipol, and colestimide, at maximum dose, lower LDL-C by 15–21%, and raise HDL-C by 3–9% and TG by 2 ...

High LDL-C and Lp(a) cholesterol levels could raise your risk of heart disease. These “bad” cholesterol types can block ...

The analysis indicated that the benefits of IPE were consistent regardless of baseline LDL-C levels, supporting its use as a complementary therapy alongside existing LDL-C lowering treatments.

Amarin (AMRN) highlighted recently published data in the Journal of the American Heart Association showing in a post-hoc analysis of the ...

December 31, 2024 -- NAARDEN, the Netherlands and MIAMI, Feb. 26, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical ...